Zacks Research Has Positive Outlook for CVKD FY2026 Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Equities researchers at Zacks Research raised their FY2026 earnings per share (EPS) estimates for Cadrenal Therapeutics in a note issued to investors on Friday, May 8th. Zacks Research analyst D. Bautz now anticipates that the company will earn ($4.82) per share for the year, up from their previous estimate of ($5.08). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($5.61) per share.

Cadrenal Therapeutics (NASDAQ:CVKD) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.51) by $0.47.

Several other brokerages also recently commented on CVKD. Wall Street Zen raised Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Monday, April 20th. Finally, HC Wainwright lowered their price objective on Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Cadrenal Therapeutics presently has a consensus rating of “Hold” and an average price target of $13.00.

Cadrenal Therapeutics Stock Performance

Shares of NASDAQ:CVKD opened at $5.19 on Wednesday. The business’s 50 day simple moving average is $6.02 and its two-hundred day simple moving average is $7.86. The firm has a market cap of $14.88 million, a P/E ratio of -0.92 and a beta of 1.81. Cadrenal Therapeutics has a 52-week low of $4.21 and a 52-week high of $16.25.

Institutional Trading of Cadrenal Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. DRW Securities LLC purchased a new stake in shares of Cadrenal Therapeutics during the fourth quarter valued at approximately $171,000. Citadel Advisors LLC purchased a new stake in shares of Cadrenal Therapeutics during the third quarter valued at approximately $274,000. JPMorgan Chase & Co. purchased a new stake in shares of Cadrenal Therapeutics during the third quarter valued at approximately $103,000. Finally, Geode Capital Management LLC increased its position in shares of Cadrenal Therapeutics by 14.3% during the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after acquiring an additional 1,818 shares during the last quarter. 7.92% of the stock is owned by hedge funds and other institutional investors.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.